• Policy
• Prolia and Ryaltris adjust drug pricing
• by Lee, Tak-Sun Apr 23, 2024 05:40am

• Company
• Pharmbio wins over Novartis’ Revolade in patent dispute
• by Kim, Jin-Gu Apr 23, 2024 05:37am

• Policy
• HK inno.N starts developing a Lixiana generic
• by Lee, Hye-Kyung Apr 23, 2024 05:36am

• Company
• Skyrizi approved for palmoplantar pustulosis
• by Son, Hyung-Min Apr 23, 2024 05:36am

• Company
• Novartis fosters innovative talent through focus on purpose
• by Eo, Yun-Ho Apr 23, 2024 05:36am

• Policy
• Atopic dermatitis drug Adtralza will be reimb in May
• by Lee, Jeong-Hwan Apr 22, 2024 05:45am

• Policy
• KMPG ‘We ask for the prompt reimbursement of Xpovio’
• by Kim, Jung-Ju Apr 22, 2024 05:45am

• Company
• AstraZeneca focuses on improving competitiveness of NMOSD
• by Eo, Yun-Ho Apr 22, 2024 05:45am

• Policy
• Will the 37th new drug in Korea receive approval?
• by Lee, Hye-Kyung Apr 22, 2024 05:45am

• Company
• Will Padcev be deemed cost-effective and receive DREC review
• by Eo, Yun-Ho Apr 22, 2024 05:45am